


| DESCRIPTION               |  |
|---------------------------|--|
| <b>Species Reactivity</b> | Human  |
| <b>Specificity</b>        | Detects human PD-ECGF/Thymidine Phosphorylase in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with _____ is observed.    |
| <b>Source</b>             | Polyclonal Goat IgG  |
| <b>Purification</b>       | Protein A or G purified  |
| <b>Immunogen</b>          | <i>S. frugiperda</i> insect ovarian cell line Sf 21-derived recombinant human PD-ECGF/Thymidine Phosphorylase Ala11-Gln482<br>Accession # P19971.2 |
| <b>Endotoxin Level</b>    | <0.10 EU per 1 µg of the antibody by the LAL method.   |
| <b>Formulation</b>        | Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.  |

**APPLICATIONS**

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

|                       | Recommended Concentration | Sample   |
|-----------------------|---------------------------|--|
| <b>Western Blot</b>   | 1 µg/mL                   | Recombinant Human PD-ECGF/Thymidine Phosphorylase (Catalog # 229-PE)   |
| <b>Neutralization</b> |                           | Measured by its ability to neutralize PD-ECGF/Thymidine Phosphorylase-induced proliferation in HUVEC human umbilical vein endothelial cells. Usuki, K. <i>et al.</i> (1990) Cell Regulation 1:577. The Neutralization Dose (ND <sub>50</sub> ) is typically 10-25 µg/mL in the presence of 150 ng/mL Recombinant Human PD-ECGF/Thymidine Phosphorylase . |

**DATA**



**PREPARATION AND STORAGE**

|                                |   |
|--------------------------------|---|
| <b>Reconstitution</b>          | Reconstitute at 1 mg/mL in sterile PBS.   |
| <b>Shipping</b>                | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.   |
| <b>Stability &amp; Storage</b> | <p><b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b></p> <ul style="list-style-type: none"> <li>• 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>• 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>• 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul> |

**BACKGROUND**

PD-ECGF, also known as TPase and gliostatin, is produced by placenta, platelets, liver, lung, spleen, lymph nodes, and peripheral lymphocytes. It is overexpressed by many tumors in response to chemical or physical stress. PD-ECGF promotes endothelial cell proliferation and chemotaxis and promotes angiogenesis. PD-ECGF is a key enzyme in the pyrimidine nucleoside salvage pathway. It also metabolizes and inactivates chemotherapeutic drugs such as 5-fluorouracil and its derivatives. The human PD-ECGF cDNA encodes a 482 amino acid (aa) polypeptide with a 10 aa propeptide. The protein is localized mostly within the producer cells. N-terminal truncation, resulting in proteins lacking 10 aa and 6 aa, has been observed in PD-ECGF purified from platelets and placenta, respectively. In solution, PD-ECGF exists as a non-disulfide linked homodimer. The latter protein was purified from quiescent astrocytes and described as an astrocyte and astrocytoma cell growth inhibitor based on its ability to inhibit <sup>3</sup>H-thymidine incorporation.

**References:**

1. Haraguchi, M. *et al.* (1994) *Nature* **368**:198.
2. Toi, M. *et al.* (2005) *Lancet Oncol.* **6**:158.
3. Akiyama, S. *et al.* (2004) *Canc. Sci.* **95**:851.